首页 > 最新文献

Expert Opinion on Therapeutic Targets最新文献

英文 中文
New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand? 动脉粥样硬化中降脂和抗炎疗法的新目标和作用机制:该领域的现状如何?
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 Epub Date: 2024-06-04 DOI: 10.1080/14728222.2024.2362644
Stephen J Nicholls, Adam J Nelson

Introduction: Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality worldwide, despite widespread use of statins. There is a need to develop additional therapeutic strategies that will complement statins to achieve more effective reductions in cardiovascular risk.

Areas covered: This review provides a comprehensive summary of current areas of therapeutic development targeting both lipid and inflammatory factors implicated in the pathogenesis of atherosclerosis. In addition to develop of novel approaches that will produce more effective lowering of low-density lipoprotein cholesterol, clinical trials are currently evaluating the potential to target other atherogenic lipid parameters such as triglyceride-rich lipoproteins and Lp(a), in addition to promoting the biological properties of high-density lipoproteins. Targeting inflammation within the vascular wall has emerged as a new frontier in cardiovascular prevention, with early evidence that use of anti-inflammatory agents have the potential to reduce cardiovascular risk.

Expert opinion: Clinical practice has an increasing array of therapeutic tools to achieve more effective lowering of low-density lipoprotein cholesterol for high-risk patients. In addition, clinical trials have the potential to deliver a range of additional agents to the clinic, that target alternative lipid and inflammatory mediators. This will permit the potential to personalize cardiovascular prevention.

导言:尽管他汀类药物被广泛使用,但动脉粥样硬化性心血管疾病仍然是全球发病率和死亡率的主要原因。为了更有效地降低心血管风险,有必要开发更多的治疗策略来补充他汀类药物:本综述全面总结了目前针对与动脉粥样硬化发病机制有关的脂质和炎症因素的治疗开发领域。除了开发能更有效降低低密度脂蛋白胆固醇的新方法外,目前的临床试验还在评估针对其他致动脉粥样硬化脂质参数(如富含甘油三酯的脂蛋白和脂蛋白(a))的可能性,以及促进高密度脂蛋白生物特性的可能性。针对血管壁内的炎症已成为心血管预防的一个新领域,早期证据表明,使用抗炎药物有可能降低心血管风险:临床实践中,有越来越多的治疗手段可以更有效地降低高危患者的低密度脂蛋白胆固醇。此外,临床试验有可能为临床提供一系列针对其他脂质和炎症介质的额外药物。这将为个性化预防心血管疾病提供可能。
{"title":"New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?","authors":"Stephen J Nicholls, Adam J Nelson","doi":"10.1080/14728222.2024.2362644","DOIUrl":"10.1080/14728222.2024.2362644","url":null,"abstract":"<p><strong>Introduction: </strong>Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality worldwide, despite widespread use of statins. There is a need to develop additional therapeutic strategies that will complement statins to achieve more effective reductions in cardiovascular risk.</p><p><strong>Areas covered: </strong>This review provides a comprehensive summary of current areas of therapeutic development targeting both lipid and inflammatory factors implicated in the pathogenesis of atherosclerosis. In addition to develop of novel approaches that will produce more effective lowering of low-density lipoprotein cholesterol, clinical trials are currently evaluating the potential to target other atherogenic lipid parameters such as triglyceride-rich lipoproteins and Lp(a), in addition to promoting the biological properties of high-density lipoproteins. Targeting inflammation within the vascular wall has emerged as a new frontier in cardiovascular prevention, with early evidence that use of anti-inflammatory agents have the potential to reduce cardiovascular risk.</p><p><strong>Expert opinion: </strong>Clinical practice has an increasing array of therapeutic tools to achieve more effective lowering of low-density lipoprotein cholesterol for high-risk patients. In addition, clinical trials have the potential to deliver a range of additional agents to the clinic, that target alternative lipid and inflammatory mediators. This will permit the potential to personalize cardiovascular prevention.</p>","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"375-384"},"PeriodicalIF":5.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
S100A1: a promising therapeutic target for heart failure S100A1:有望治疗心力衰竭的靶点
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-19 DOI: 10.1080/14728222.2024.2345746
Dorothea Noll, Dorothea Kehr, Patrick Most, Julia Ritterhoff
Published in Expert Opinion on Therapeutic Targets (Just accepted, 2024)
发表于《治疗靶点专家意见》(刚刚接受,2024 年)
{"title":"S100A1: a promising therapeutic target for heart failure","authors":"Dorothea Noll, Dorothea Kehr, Patrick Most, Julia Ritterhoff","doi":"10.1080/14728222.2024.2345746","DOIUrl":"https://doi.org/10.1080/14728222.2024.2345746","url":null,"abstract":"Published in Expert Opinion on Therapeutic Targets (Just accepted, 2024)","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"17 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular drilling to combat salmonella typhi biofilm using L-Asparaginase via multiple targeting process 利用 L-天冬酰胺酶通过多重靶向过程对抗伤寒沙门氏菌生物膜的分子钻研
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-19 DOI: 10.1080/14728222.2024.2344699
Aditya Upadhyay, Dharm Pal, Awanish Kumar
Salmonella Typhibiofilm condition is showing as a major public health problem due to the developmentof antibiotic resistance and less available druggable target proteins.Therefore, we aimed to iden...
由于抗生素耐药性的产生以及可用于制药的靶蛋白的减少,嗜盐酸沙门氏菌酪脂膜病症正成为一个主要的公共卫生问题。
{"title":"Molecular drilling to combat salmonella typhi biofilm using L-Asparaginase via multiple targeting process","authors":"Aditya Upadhyay, Dharm Pal, Awanish Kumar","doi":"10.1080/14728222.2024.2344699","DOIUrl":"https://doi.org/10.1080/14728222.2024.2344699","url":null,"abstract":"Salmonella Typhibiofilm condition is showing as a major public health problem due to the developmentof antibiotic resistance and less available druggable target proteins.Therefore, we aimed to iden...","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"77 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Non-receptor tyrosine kinases in epilepsy: significance and potential as therapeutic targets 非受体酪氨酸激酶在癫痫中的作用:作为治疗靶点的意义和潜力
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-17 DOI: 10.1080/14728222.2024.2343952
Ozasvi R Shanker, Sonali Kumar, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit
Epilepsy is a chronic neurological condition characterized by a persistent propensity for seizure generation. About one-third of patients do not achieve seizure control with the first-line treatmen...
癫痫是一种慢性神经系统疾病,其特点是发作倾向持续存在。约有三分之一的患者在接受一线治疗后无法控制癫痫发作...
{"title":"Role of Non-receptor tyrosine kinases in epilepsy: significance and potential as therapeutic targets","authors":"Ozasvi R Shanker, Sonali Kumar, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit","doi":"10.1080/14728222.2024.2343952","DOIUrl":"https://doi.org/10.1080/14728222.2024.2343952","url":null,"abstract":"Epilepsy is a chronic neurological condition characterized by a persistent propensity for seizure generation. About one-third of patients do not achieve seizure control with the first-line treatmen...","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"80 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140610282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising therapeutic targets for the treatment of urine storage dysfunction: what’s the status? 治疗尿储藏功能障碍的有望治疗靶点:现状如何?
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-17 DOI: 10.1080/14728222.2024.2344698
Karl-Erik Andersson
Opinions differ on what drugs have both a rationale and a development potential for the treatment of bladder storage dysfunction.In the present review, the focus is given to small molecule blockers...
对于哪些药物具有治疗膀胱储尿功能障碍的合理性和发展潜力,众说纷纭。在本综述中,重点关注小分子阻断剂。
{"title":"Promising therapeutic targets for the treatment of urine storage dysfunction: what’s the status?","authors":"Karl-Erik Andersson","doi":"10.1080/14728222.2024.2344698","DOIUrl":"https://doi.org/10.1080/14728222.2024.2344698","url":null,"abstract":"Opinions differ on what drugs have both a rationale and a development potential for the treatment of bladder storage dysfunction.In the present review, the focus is given to small molecule blockers...","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"57 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140610671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus 抗抑郁作用的增效:NPY1R 激动剂和氯胺酮协同作用可增强腹侧海马的 TrkB 信号转导和神经发生
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-16 DOI: 10.1080/14728222.2024.2342524
Carlos Arrabal-Gómez, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, Natalia Garcia-Casares, Kjell Fuxe, Dasiel Borroto-Escuela, Manuel Narváez
Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays. This study explores the synergistic antidepressan...
重度抑郁症(MDD)对全球健康构成了重大挑战,目前的治疗方法往往因疗效和发病延迟而受到限制。这项研究探讨了协同抗抑郁剂的作用。
{"title":"Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus","authors":"Carlos Arrabal-Gómez, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, Natalia Garcia-Casares, Kjell Fuxe, Dasiel Borroto-Escuela, Manuel Narváez","doi":"10.1080/14728222.2024.2342524","DOIUrl":"https://doi.org/10.1080/14728222.2024.2342524","url":null,"abstract":"Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays. This study explores the synergistic antidepressan...","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"56 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140599131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for Major depressive disorder 通过长期共同激活加拉宁 2 (GALR2) 和神经肽 Y1 受体 (NPY1R),提高神经元存活率和 BDNF:重度抑郁障碍的潜在治疗靶点
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-15 DOI: 10.1080/14728222.2024.2342517
Dasiel Borroto-Escuela, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, Miguel Angel Barbancho-Fernández, Kjell Fuxe, Manuel Narváez
Major Depressive Disorder (MDD) is a prevalent and debilitating condition, necessitating novel therapeutic strategies due to the limited efficacy and adverse effects of current treatments. We explo...
重度抑郁障碍(MDD)是一种普遍存在且使人衰弱的疾病,由于目前的治疗方法疗效有限且存在不良反应,因此需要新的治疗策略。我们探索了...
{"title":"Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for Major depressive disorder","authors":"Dasiel Borroto-Escuela, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, Miguel Angel Barbancho-Fernández, Kjell Fuxe, Manuel Narváez","doi":"10.1080/14728222.2024.2342517","DOIUrl":"https://doi.org/10.1080/14728222.2024.2342517","url":null,"abstract":"Major Depressive Disorder (MDD) is a prevalent and debilitating condition, necessitating novel therapeutic strategies due to the limited efficacy and adverse effects of current treatments. We explo...","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"96 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140598729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An update on the development on tubulin inhibitors for the treatment of solid tumors 治疗实体瘤的微管蛋白抑制剂的最新进展
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-15 DOI: 10.1080/14728222.2024.2341630
Prasanna Anjaneyulu Yakkalaa, Shaik Rahaman, P.S. Lakshmi Soukya, Sajeli Ahil Begum, A Kamal
Microtubules play a vital role in cancer therapeutics. They are implicated in tumorigenesis, thus inhibiting tubulin polymerization in cancer cells, and have now become a significant target for ant...
微管在癌症治疗中发挥着重要作用。它们与肿瘤发生有关,因此抑制了癌细胞中的微管蛋白聚合,现在已成为抗肿瘤药物的一个重要靶点。
{"title":"An update on the development on tubulin inhibitors for the treatment of solid tumors","authors":"Prasanna Anjaneyulu Yakkalaa, Shaik Rahaman, P.S. Lakshmi Soukya, Sajeli Ahil Begum, A Kamal","doi":"10.1080/14728222.2024.2341630","DOIUrl":"https://doi.org/10.1080/14728222.2024.2341630","url":null,"abstract":"Microtubules play a vital role in cancer therapeutics. They are implicated in tumorigenesis, thus inhibiting tubulin polymerization in cancer cells, and have now become a significant target for ant...","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"116 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140599220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guillain-Barré syndrome: immunopathogenesis and therapeutic targets. 格林-巴利综合征:免疫发病机制和治疗目标。
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-01 Epub Date: 2024-03-18 DOI: 10.1080/14728222.2024.2330435
Shan Liu, Wei Wei Zhang, Linpei Jia, Hong-Liang Zhang

Introduction: Guillain-Barré syndrome (GBS) is a group of acute immune-mediated disorders in the peripheral nervous system. Both infectious and noninfectious factors are associated with GBS, which may act as triggers of autoimmune responses leading to neural damage and dysfunction.

Areas covered: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccines as well as flaviviruses have been associated with GBS, although a robust conclusion has yet to be reached. Immunomodulatory treatments, including intravenous immunoglobulins (IVIg) and plasma exchange (PE), have long been the first-line therapies for GBS. Depending on GBS subtype and severity at initial presentation, the efficacy of IVIg and PE can be variable. Several new therapies showing benefits to experimental animals merit further investigation before translation into clinical practice. We review the state-of-the-art knowledge on the immunopathogenesis of GBS in the context of coronavirus disease 2019 (COVID-19). Immunomodulatory therapies in GBS, including IVIg, PE, corticosteroids, and potential therapies, are summarized.

Expert opinion: The association with SARS-CoV-2 remains uncertain, with geographical differences that are difficult to explain. Evidence and guidelines are lacking for the decision-making of initiating immunomodulatory therapies in mildly affected patients or patients with regional subtypes of GBS.

导言吉兰-巴雷综合征(GBS)是一组由免疫介导的急性周围神经系统疾病。吉兰-巴雷综合征与感染性和非感染性因素都有关系,这些因素可能会引发自身免疫反应,导致神经损伤和功能障碍:严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)及其疫苗以及黄病毒都与 GBS 有关,但尚未得出可靠的结论。免疫调节治疗,包括静脉注射免疫球蛋白(IVIg)和血浆置换(PE),长期以来一直是 GBS 的一线疗法。根据 GBS 亚型和初次发病时的严重程度,静脉注射免疫球蛋白和血浆置换的疗效可能会有所不同。有几种新疗法显示出对实验动物的益处,值得进一步研究,然后再应用于临床实践。我们结合 2019 年冠状病毒疾病(COVID-19)回顾了有关 GBS 免疫发病机制的最新知识。总结了 GBS 的免疫调节疗法,包括 IVIg、PE、皮质类固醇和潜在疗法:与SARS-CoV-2的关系仍不确定,地域差异难以解释。专家观点:与 SARS-CoV-2 的关系仍不确定,地域差异难以解释。对于轻度患者或 GBS 区域亚型患者启动免疫调节疗法的决策缺乏证据和指南。
{"title":"Guillain-Barré syndrome: immunopathogenesis and therapeutic targets.","authors":"Shan Liu, Wei Wei Zhang, Linpei Jia, Hong-Liang Zhang","doi":"10.1080/14728222.2024.2330435","DOIUrl":"10.1080/14728222.2024.2330435","url":null,"abstract":"<p><strong>Introduction: </strong>Guillain-Barré syndrome (GBS) is a group of acute immune-mediated disorders in the peripheral nervous system. Both infectious and noninfectious factors are associated with GBS, which may act as triggers of autoimmune responses leading to neural damage and dysfunction.</p><p><strong>Areas covered: </strong>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccines as well as flaviviruses have been associated with GBS, although a robust conclusion has yet to be reached. Immunomodulatory treatments, including intravenous immunoglobulins (IVIg) and plasma exchange (PE), have long been the first-line therapies for GBS. Depending on GBS subtype and severity at initial presentation, the efficacy of IVIg and PE can be variable. Several new therapies showing benefits to experimental animals merit further investigation before translation into clinical practice. We review the state-of-the-art knowledge on the immunopathogenesis of GBS in the context of coronavirus disease 2019 (COVID-19). Immunomodulatory therapies in GBS, including IVIg, PE, corticosteroids, and potential therapies, are summarized.</p><p><strong>Expert opinion: </strong>The association with SARS-CoV-2 remains uncertain, with geographical differences that are difficult to explain. Evidence and guidelines are lacking for the decision-making of initiating immunomodulatory therapies in mildly affected patients or patients with regional subtypes of GBS.</p>","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"131-143"},"PeriodicalIF":5.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma. 基于 microRNA 的疗法对肝衰竭综合征和肝细胞癌患者的挑战和潜力。
IF 5.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-01 Epub Date: 2024-03-19 DOI: 10.1080/14728222.2024.2331598
Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare

Introduction: Morbidity and mortality from liver disease continues to rise worldwide. There are currently limited curative treatments for patients with liver failure syndromes, encompassing acute liver failure and decompensated cirrhosis states, outside of transplantation. Whilst there have been improvements in therapeutic options for patients with hepatocellular carcinoma (HCC), there remain challenges necessitating novel therapeutic agents. microRNA have long been seen as potential therapeutic targets but there has been limited clinical translation.

Areas covered: We will discuss the limitations of conventional non-transplant management of patients with liver failure syndromes and HCC. We will provide an overview of microRNA and the challenges in developing and delivering microRNA-based therapeutic agents. We will finally provide an overview of microRNA-based therapeutic agents which have progressed to clinical trials.

Expert opinion: microRNA have great potential to be developed into therapeutic agents due to their association with critical biological processes which govern health and disease. Utilizing microRNA sponges to target multiple microRNA associated with specific biological processes may improve their therapeutic efficacy. However, there needs to be significant improvements in delivery systems to ensure the safe delivery of microRNA to target sites and minimize systemic distribution. This currently significantly impacts the clinical translation of microRNA-based therapeutic agents.

导言:全球肝病的发病率和死亡率持续上升。目前,对于肝衰竭综合征(包括急性肝衰竭和失代偿期肝硬化)患者,除移植手术外,治疗手段十分有限。虽然肝细胞癌(HCC)患者的治疗方案有所改善,但仍面临着需要新型治疗药物的挑战。microRNA 长期以来一直被视为潜在的治疗靶点,但临床转化有限:我们将讨论肝衰竭综合征和 HCC 患者的传统非移植治疗的局限性。我们将概述 microRNA 以及开发和提供基于 microRNA 的治疗药物所面临的挑战。最后,我们将概述已进入临床试验阶段的基于 microRNA 的治疗药物。专家观点:microRNA 与支配健康和疾病的关键生物过程有关,因此具有开发成治疗药物的巨大潜力。利用 microRNA 海绵来靶向与特定生物过程相关的多种 microRNA 可能会提高其疗效。不过,还需要对递送系统进行重大改进,以确保将 microRNA 安全递送到靶点,并尽量减少其在全身的分布。目前,这极大地影响了基于 microRNA 的治疗药物的临床转化。
{"title":"The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma.","authors":"Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare","doi":"10.1080/14728222.2024.2331598","DOIUrl":"10.1080/14728222.2024.2331598","url":null,"abstract":"<p><strong>Introduction: </strong>Morbidity and mortality from liver disease continues to rise worldwide. There are currently limited curative treatments for patients with liver failure syndromes, encompassing acute liver failure and decompensated cirrhosis states, outside of transplantation. Whilst there have been improvements in therapeutic options for patients with hepatocellular carcinoma (HCC), there remain challenges necessitating novel therapeutic agents. microRNA have long been seen as potential therapeutic targets but there has been limited clinical translation.</p><p><strong>Areas covered: </strong>We will discuss the limitations of conventional non-transplant management of patients with liver failure syndromes and HCC. We will provide an overview of microRNA and the challenges in developing and delivering microRNA-based therapeutic agents. We will finally provide an overview of microRNA-based therapeutic agents which have progressed to clinical trials.</p><p><strong>Expert opinion: </strong>microRNA have great potential to be developed into therapeutic agents due to their association with critical biological processes which govern health and disease. Utilizing microRNA sponges to target multiple microRNA associated with specific biological processes may improve their therapeutic efficacy. However, there needs to be significant improvements in delivery systems to ensure the safe delivery of microRNA to target sites and minimize systemic distribution. This currently significantly impacts the clinical translation of microRNA-based therapeutic agents.</p>","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"179-191"},"PeriodicalIF":5.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140131115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Opinion on Therapeutic Targets
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1